What is the global market size of Biodefense Market?

Biodefense Market size was valued at USD 14.27 billion in 2021 and is poised to grow from USD 15 billion in 2022 to USD 22.33 billion by 2030, growing at a CAGR of 5.1% during the forecast period (2023-2030).

Who are the key vendors in the Global Biodefense Market?

The competitive landscape of the global biodefense market is characterized by intense competition among various stakeholders, including government organizations, research institutions, and private sector entities. The market is witnessing a significant influx of investments, driving innovation and the development of advanced biodefense technologies. Collaborations and partnerships between industry players and government agencies are common, facilitating knowledge exchange, resource sharing, and the development of comprehensive biodefense strategies. Additionally, regulatory frameworks and standards play a crucial role in shaping the competitive dynamics of the market, ensuring the safety and efficacy of biodefense products and solutions. The market's competitive intensity is further fueled by the constant evolution of biological threats and the need for continuous research and development to stay ahead of emerging risks. 'XOMA Corporation (US)', 'Altimmune Inc. (US)', 'Emergent Biosolutions Inc. (US)', 'Dynavax Technologies Corporation (US)', 'SIGA Technologies (US)', 'Elusys Therapeutics Inc. (US)', 'Ichor Medical Systems (US)', 'Dynport Vaccine Company (US)', 'Cleveland Biolabs (US)', 'Bavarian Nordic (Denmark)', 'Ology Bioservices (US)', 'Alnylam Pharmaceuticals Inc. (US)', 'Evolva (Switzerland)', 'BioCryst Pharmaceuticals Inc. (US)', 'PharmAthene Inc. (US)', 'Profectus Biosciences Inc. (US)', 'NanoViricides Inc. (US)', 'Takeda Pharmaceutical Company Limited (Japan)', 'Sanofi Pasteur (France)', 'GlaxoSmithKline (UK)'

What is the key driver of Global Biodefense Market?

One key driver of the global biodefense market is the increasing recognition of the potential catastrophic consequences of biological threats. Governments, defense agencies, and healthcare organizations worldwide are investing heavily in biodefense capabilities to mitigate the risks posed by bioterrorism, pandemics, and other biological emergencies.

What is the key market trend for Global Biodefense Market?

One key market trend in the global biodefense market is the increasing focus on the development of advanced diagnostic technologies. There is a growing emphasis on the rapid and accurate detection of biological agents to enable early intervention and effective response during biodefense incidents. Innovative diagnostic tools, such as point-of-care testing devices and molecular diagnostics, are being developed to enhance the speed and accuracy of identifying potential biological threats. This trend aims to strengthen surveillance systems and improve the overall preparedness and response capabilities in biodefense scenarios.

Which region accounted for the largest share in Global Biodefense Market?

North America dominated the global biodefense market. North America holds a significant market share due to its well-established healthcare infrastructure, robust research and development capabilities, and strong emphasis on national security. The region has witnessed substantial investments in biodefense technologies, including vaccines, therapeutics, and detection systems, driven by proactive government initiatives, collaborations with industry stakeholders, and a high level of preparedness against bioterrorism threats.

Biodefense Market Size, Share, Growth Analysis, By Type(Anthrax, Smallpox, Botulism, Radiation/Nuclear), By Application(Hospitals and clinics, Ambulatory Care Centers, Others), By Region - Industry Forecast 2024-2031

Report ID: SQMIG35H2213 | Region: Global | Published Date: September, 2024
Pages: 157 | Tables: 63 | Figures: 75

Biodefense Market News

The US Food and Drug Administration approved the BioThrax vaccine developed by Emergent BioSolutions Inc., (EBS), in March 2024 for the prevention of anthrax illness both before as well as after exposure to it. The company is carrying out active activities that can help it to retain its top status for being the leading supplier of anthrax vaccinations to other organizations.
The US FDA approved T2 Biosystems Inc.'s T2Biothreat Panel in September 2023. The T2Biothreat identifies six high-priority biothreating diseases in the US. The T2Dx is a molecular diagnostic test for direct-from-blood that can identify and distinguish the six biothreat diseases, including the species responsible for anthrax, from a single sample.
The US Food and Drug Administration has accepted for review the Biologics License Application for AV7909 or Anthrax Vaccine Adsorbed, Adjuvanted by Emergent BioSolutions Inc. (NYSE: EBS), it notified through a press release issued in June 2022.

Biodefense Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Biodefense Market size was valued at USD 15.22 billion in 2022 and is poised to grow from USD 15.99 billion in 2023 to USD 23.67 billion by 2031, growing at a CAGR of 5.03% during the forecast period (2024-2031).

Competition in the biodefense industry is marked by major companies and newly emerging companies' emphasis on innovative solutions. While innovative companies introduce new technologies into the market, established companies exploit large resources and experience. Increases in public-private partnerships are presently working to strengthen research and development endeavors. Such a dynamic environment motivates continuous innovation and a run for appropriate handling of changing biological threats. 'XOMA Corporation ', 'Altimmune Inc. ', 'Emergent Biosolutions Inc. ', 'Dynavax Technologies Corporation ', 'SIGA Technologies ', 'Elusys Therapeutics Inc. ', 'Ichor Medical Systems ', 'Dynport Vaccine Company ', 'Cleveland Biolabs ', 'Bavarian Nordic ', 'Ology Bioservices ', 'Alnylam Pharmaceuticals Inc. ', 'BioCryst Pharmaceuticals Inc. ', 'PharmAthene Inc. ', 'Profectus Biosciences Inc. ', 'NanoViricides Inc. ', 'Takeda Pharmaceutical Company Limited ', 'Sanofi Pasteur ', 'GlaxoSmithKline'

The federal and state government must incur huge expenses towards biodefense programs to strengthen national and public health security. This expenditure is the financing needed to develop vaccines, diagnostics, and treatments so that healthcare systems are ready for any biological threats. Governments have invested in emergency planning infrastructure and training that sketches out a climate under which innovative biodefense solutions can grow. It would eventually lead to building resistance against biological attacks or pandemics.

Modes of Personalized Medicine: One of the major biodefense market trends is the increasing popularity for personalized medicine. It is the molding that gives shape to the development of the customized vaccines and treatments focused on specific groups of people or biological threats. This technology presents many more effective and efficient response mechanisms to infectious illness and emphasizes tailored health solutions. Experts predict that when genomics and biotechnology become advanced, they will be able to create a vaccine. That vaccine will not only be highly effective in fighting off various infections but also specifically tailor-made for the genetic makeup of different populations.

With a commanding 86.1% biodefense market share in 2023, North America led the industry and is predicted to grow with a strong CAGR throughout the forecast period. Among the many factors constituting this superiority lies huge federal outlays for enhancing public health security and technical advancements that enhance biodefense capabilities. Furthermore, growing public knowledge about biological risks continues to fuel increasing demand for effective response and preparedness plans. Such big giants in the field offer the market a much-required boost by enforcing innovation and newer goods and services upon the earth. All these contribute to reifying North America as the global leader in the biodefense industry.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Biodefense Market Size, Share, Growth Analysis, By Type(Anthrax, Smallpox, Botulism, Radiation/Nuclear), By Application(Hospitals and clinics, Ambulatory Care Centers, Others), By Region - Industry Forecast 2024-2031

Biodefense Market News

Biodefense Market Report Snapshots

Want to customize this report?

FAQs

What is the global market size of Biodefense Market?

Who are the key vendors in the Biodefense Market?

What is the key driver of Biodefense Market?

What is the key market trend for Biodefense Market?

Which region accounted for the largest share in Biodefense Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300